What is Herceptin Biosimilar Market Scope?
Herceptin is a monoclonal antibody and the original brand of trastuzumab, a biological medicine used to treat specific types of breast and gastric cancer, in specific patients and used in conjunction with prescribed treatment regimes. Herceptin is what’s called a biologic drug, and it is made from living organisms, in this case, a protein from a mouse cell. A monoclonal antibody is a type of protein made in the lab that can bind to substances in the body, including cancer cells.
The Herceptin Biosimilar market study is being classified by Type (Herzuma, Kanjinti, Ogivri, Ontruzant and Trazimera), by Application (Anti-Arthritis Drugs, Anti-Cancer Drugs, Respiratory Products, Anti-Infective Drugs, Central Nervous System Drugs, Cardiovascular Products and Other) and major geographies with country level break-up.
Research Analyst at AMA predicts that Players from United States will contribute to the maximum growth of Global Herceptin Biosimilar market throughout the predicted period.
Teva Pharmaceutical Industries, Ltd. (Israel), Amgen Inc. (United States), Celltrion Inc. (South Korea), Mylan, Inc. (United States), Pfizer Inc. (United States), Merck & Co., Inc. (United States), Intas Pharmaceuticals Limited (India), Gedeon Richter Plc (Hungary), Mabion SA (Poland), Roche Holding AG and, Par Pharmaceutical, Inc. (United States) and Hospira, Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Biocon Limited (India), Dr. Reddy’s Laboratories (India), Sandoz International GmbH (Germany), Apotex, Inc. (Canada), Watson Pharmaceuticals, Ltd. (India), Novartis (Switzerland), Fresenius SE & Co. KGaA (Germany), Sun Pharmaceutical Industries (India), Ranbaxy Laboratories, Ltd (India), Actavis (Ireland), Cipla (India), Amneal Pharmaceuticals (United States), Aurobindo Pharma Limited (India), Aspen Pharmacare Holdings Limited (South Africa), Lupin Limited (India) and Zydus Cadila (India).
Analyst at AMA have segmented the market study of Global Herceptin Biosimilar market by Type, Application and Region.
On the basis of geography, the market of Herceptin Biosimilar has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
Market Influencers and their development strategies
On 16th March 2020, Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and Celltrion Healthcare, Co., Ltd. have announced that HERZUMA (trastuzumab-pkrb) for Injection, a biosimilar to HERCEPTIN, is now available in the United States.
On 2nd December 2019, Mylan N.V. and Biocon Ltd. have announced the U.S. launch of Ogivri (trastuzumab-dkst), a biosimilar to Herceptin (trastuzumab). Ogivri is available in a 420mg multi-dose vial and a 150mg single-dose vial in order to provide patient dosing and treatment flexibility.
Influencing Market Trend
- Advent of Robotic Process Automation (RPA)
- Rising Demand for Herceptin Drugs in Emerging Countries such as China and India
- Increasing Chronic Diseases such as Cancer
- Government Promoting the Pharmaceutical Sector
- Stringent Governmental Regulations
- Herceptin may Cause Serious Heart Problems
Key Target AudienceHerceptin Biosimilar Manufacturers, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Other
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.